In a significant step forward for lung cancer treatment, the US Food and Drug Administration (FDA) has expanded its approval of Bristol Myers Squibb’s Opdivo (nivolumab). The latest approval allows the immunotherapy to be used in adult patients with resectable non-small cell lung cancer (NSCLC) in combination with platinum-doublet chemotherapy as part of a perioperative […]
AstraZeneca’s datopotamab deruxtecan (Dato-DXd), a cutting-edge TROP2-directed antibody-drug conjugate, has demonstrated encouraging overall survival results in the TROPION-Lung01 Phase III trial, which focused on patients with advanced nonsquamous non-small cell lung cancer (NSCLC). The study, conducted in collaboration with Daiichi Sankyo, compared datopotamab deruxtecan with docetaxel, the standard chemotherapy, revealing a median overall survival (OS) […]
The U.S. Food and Drug Administration (FDA) has approved the combination of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) as a first-line therapy for adults with advanced non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) mutations. This approval marks a significant advancement in the treatment landscape for patients with EGFR-mutated NSCLC, providing a […]
Tempus, a pioneer in artificial intelligence and precision medicine, has announced an expansion of its collaboration with pharmaceutical giant AstraZeneca. This enhanced partnership focuses on utilizing Tempus Next, a care pathway intelligence platform, to facilitate the delivery of biomarker testing for patients with non-small cell lung cancer (NSCLC), addressing critical care gaps. Enhancing Precision Medicine […]
Dizal, a prominent biopharmaceutical company listed on the Shanghai Stock Exchange (SSE:688192), has announced significant clinical results from its WU-KONG1 Part B (WU-KONG1B) study of sunvozertinib, showcasing substantial efficacy in treating non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (exon20ins). The findings were presented at the 2024 American Society of Clinical Oncology […]
Bristol Myers Squibb (NYSE: BMY) announced that its Phase 3 CheckMate -73L trial did not achieve its primary endpoint of progression-free survival (PFS) in patients with unresectable, locally advanced stage III non-small cell lung cancer (NSCLC). This clinical trial evaluated the efficacy of Opdivo (nivolumab) combined with concurrent chemoradiotherapy (CCRT), followed by Opdivo plus Yervoy […]
Bristol Myers Squibb (NYSE: BMY) has reached a pivotal milestone in the treatment of non-small cell lung cancer (NSCLC) with its announcement regarding the KRYSTAL-12 study’s success. The study focused on evaluating KRAZATI (adagrasib) as a monotherapy for patients with pretreated locally advanced or metastatic NSCLC harboring a KRASG12C mutation. KRAZATI met the primary endpoint […]
InnoCare Pharma, listed on both the Hong Kong Stock Exchange (HKEX: 09969) and the Shanghai Stock Exchange (SSE: 688428), along with ArriVent BioPharma, Inc. (Nasdaq: AVBP), has announced the commencement of a Phase 1b clinical study in China. This study marks the first time a patient has been dosed with a novel therapeutic combination targeting […]
Avistone Biotechnology Co. Ltd., a precision oncology therapeutics company, has announced the conditional approval from the National Medical Products Administration (NMPA) of China for commercializing Vebreltinib to treat patients with MET exon 14 skipping non-small cell lung cancer (NSCLC). Pivotal Phase II Study Results Underpinning Approval The NMPA’s decision was influenced by the positive outcomes […]
The European Union (EU) has given its nod to ENHERTU (trastuzumab deruxtecan) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) that have an activating HER2 (ERBB2) mutation, following platinum-based chemotherapy treatment with or without immunotherapy. This significant decision is backed by the positive outcomes of the DESTINY-Lung02 phase 2 trial, […]